
## Jun-ichi Nishimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12792/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 2022, 107, 1483-1488.	3.5	5
2	Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. British Journal of Haematology, 2022, 196, 264-265.	2.5	7
3	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2022, 13, 204062072210910.	2.5	10
4	Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement <scp>C5</scp> polymorphism: Subanalysis of the phase 1/2 <scp>COMPOSER</scp> study. British Journal of Haematology, 2022, 198, .	2.5	4
5	Pegcetacoplan versus Eculizumab in PNH. New England Journal of Medicine, 2021, 385, 1723-1726.	27.0	15
6	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood, 2020, 135, 912-920.	1.4	73
7	Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors. Blood, 2020, 136. 43-44.	1.4	3
8	Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. International Journal of Hematology, 2019, 110, 411-418.	1.6	9
9	Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. Journal of Clinical Investigation, 2019, 129, 5123-5136.	8.2	36
10	The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2018, 132, 535-535.	1.4	8
11	Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. International Journal of Hematology, 2016, 104, 548-558.	1.6	27
12	C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin. Blood, 2015, 126, 1209-1209.	1.4	4
13	Genetic Variants in C5 and Poor Response to Eculizumab. New England Journal of Medicine, 2014, 370, 632-639.	27.0	322
14	A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH. Blood, 2012, 120, 3197-3197.	1.4	3
15	Crucial Role of Complement Receptor Type 1 On the Accumulation of Complement Component 3 On Erythrocytes in Patients with PNH Treated with Eculizumab. Blood, 2012, 120, 988-988.	1.4	0
16	Expression of HMGA2 In Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2010, 116, 4242-4242.	1.4	0
17	Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study Blood, 2009, 114, 1980-1980.	1.4	3
18	Wnt Pathway Is Upregulated in Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria Blood, 2009, 114, 1987-1987.	1.4	3

Jun-ichi Nishimura

#	Article	IF	CITATIONS
19	Expression of HMGA2 in Blood Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria Blood, 2008, 112, 3439-3439.	1.4	Ο
20	Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood, 2006, 108, 4232-4236.	1.4	147
21	Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood, 2005, 106, 3699-3709.	1.4	652
22	Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan. Medicine (United States), 2004, 83, 193-207.	1.0	199
23	Human PIC-U and Yeast Cdc91p Are the Fifth Subunit of GPI Transamidase That Attaches GPI-Anchors to Proteins. Molecular Biology of the Cell, 2003, 14, 1780-1789.	2.1	109